

27 July 2021

Quarterly Activity Report and Appendix 4C for 2Q 2021

Doctor Care Anywhere performs well in 2Q with strong market demand. Reaffirms guidance of at least 100% revenue growth for FY2021

Highlights

- Unaudited Underlying Revenue of £4.8 million in 2Q 2021 (AUS\$8.9 million); up 8.1% on 1Q 2021; 78.1% on 2Q 2020
- Activated Lives of 558,700; up 12.7% on 1Q 2021; 90.1% on 2Q 2020
- Record 2,146 consultations conducted on a single day; up 33.0% on previous highest day and record consultation volumes seen across all days of the week at quarter end, demonstrating continued demand as UK economy unlocks
- 89,400 consultations delivered during 2Q 2021, down 1.3% on 1Q 2021 due to an anticipated shortage of GPs re-called to conduct national vaccination programme; up 69.1% on 2Q 2020
- Recruitment drive added 71 new GPs to the platform in 2Q 2021 bringing panel total to 315
- 100 additional GPs in the pipeline, which should provide up to 45,000 appointment capacity per month by 3Q end, with further recruitment underway
- Diagnostic referral volumes up by 34.4% on 1Q 2021
- Key IPO commitment met with launch of Mental Health proposition
- Strengthened Nuffield Health partnership with agreement for unique integrated primary care service
- Cash position of £31.5 million (AUS\$58.7 million) as at 30 June 2021
- Reaffirms guidance for FY 2021 revenue growth of at least 100% above FY 2020

Doctor Care Anywhere Group PLC (ASX:DOC, “DOC”, “Doctor Care Anywhere” or “the Company”), is pleased to provide the following update on trading for the quarter ended 30 June 2021 (“2Q 2021”).

This Quarterly Activity Report and Appendix 4C is prepared in GBP in accordance with International Financial Reporting Standards in conformity of the requirements of the Companies Act 2006 (UK). All figures expressed in Australian Dollars (“AUS\$”) have been converted from British Pounds Sterling at an exchange rate of AUD:GBP 0.54, other than where noted.

Commenting on the performance and outlook, CEO Dr Bayju Thakar, said:

“Our outlook for 2021 remains positive following a robust performance in a quarter during which patient demand has continued to grow rapidly. A record number of daily consultations at the end of the quarter gives us visibility on growth for the second half of the year and confidence in our revenue guidance.

“Nevertheless, this has been a quarter of significant challenges as a result of the demand on GPs to deliver the national vaccination programme. This has constrained our ability to increase GP capacity as fast as we would have liked and has put pressure on our operating margins as we have been obliged to undertake a programme of incentive payments to increase capacity.

“In response to these challenges, our recruitment drive during the quarter has significantly grown our GP pool, and changes in our operating model should see operating margins normalise by the end of the year. This means we are now well-placed to provide the capacity needed to meet demand and, as we exit 2Q, we expect to see consultation growth continue to accelerate across the remainder of the year.

“At the same time, the re-opening of private secondary care services is beginning to have the anticipated positive impact on our diagnostic referral rate. The increasing complexity of our consultations reflects the ever growing waiting lists for care in the public system.

“This quarter has also seen the business sign significant commercial agreements. We have strengthened our existing partnership with one of the UK’s leading private providers, Nuffield Health, to establish a unique, integrated primary care service offering both in-person and virtual GP services. The launch of our mental health proposition fulfils a key IPO promise and has already won a new client in business services broker, Partners&. We continue to see very strong structural growth opportunities for our differentiated offer.”

Chairman Jonathan Baines, said:

“The UK primary health care system will continue to remain under extreme pressure, contributing to significantly increased demand for our service as demonstrated by the growth in activated lives and record number of daily consultations this quarter. We remain confident in our guidance for year on year revenue growth of at least 100% above FY 2020.”


Operational and Financial Performance

UK primary healthcare environment continues to drive strong demand

	Actual	Actual	% increase / (decrease) on	% increase / (decrease) on	% increase / (decrease) on
	2Q 2021 000's	1H 2021 000's	1Q 2021 (QoQ)	2Q 2020 (PCP)	1H 2020 (PCP)
Eligible Lives ¹ at Period End	2,357.1	2,357.1	(0.9%)	8.4%	8.4%
Activated Lives ² at Period End	558.7	558.7	12.7%	90.0%	90.0%
Consultations ³ by Period	89.4	179.9	(1.3%)	69.3%	131.0%

Eligible Lives remained steady at 2.4 million (1Q 2021: 2.4 million). Activated Lives at the end of 2Q 2021 were 558,700, up 12.7% on prior quarter (1Q 2021: 495,900). Growth in Activated Lives was driven by demand across DOC’s existing base of Eligible Lives.

Activated Lives (000's)



¹ **Eligible Lives** represents the total number of people who have an entitlement to use DOC’s services.


² **Activated Lives** represents the total number of people who “sign up” for DOC’s service and enter their personal details.

³ **Consultations** are the number of GP consultations delivered to patients over the period.

Consultations for 2Q 2021 were steady at 89,400, up 69.3% on 2Q20 but down 1.3% on prior quarter (1Q 2021: 90,500) due to the temporary GP supply constraints as a result of the vaccination programme, which prevented the Company from provisioning sufficient capacity to meet demand.

Progress through 2Q in recruiting and onboarding GPs leaves the Company well-positioned for the remainder of the year as demonstrated by the re-acceleration of consultations towards the end of the quarter. The Company continues to invest to meet the growing demand for the service with 100 further GPs in the pipeline, which should provide capacity for more than 45,000 appointments per month by the end of 3Q.

Consultations



Operational performance continues to drive financial metric growth

DOC's secondary care offer remains a key differentiator

	Actual	Actual	% increase / (decrease) on	% increase / (decrease) on	% increase / (decrease) on
	2Q 2021 £m's	1H 2021 £m's	1Q 2021 (QoQ)	2Q 2020 (PCP)	1H 2020 (PCP)
Revenue	4.8	11.2	(25.6%)	78.1%	145.8%
Underlying Revenue ⁴	4.8	9.2	8.1%	78.1%	135.3%
Gross Profit	1.9	5.8	(52.0%)	47.5%	130.2%
Underlying Gross Profit ⁴	1.9	3.8	(1.6%)	47.5%	102.9%
Gross Profit Margin	39.4%	51.8%	(21.6 ppt)	(8.2 ppt)	(3.5 ppt)
Underlying Gross Profit Margin ⁴	39.3%	41.2%	(3.9 ppt)	(8.2 ppt)	(6.6 ppt)
Contribution	0.5	3.4	(81.3%)	34.3%	164.6%
Underlying Contribution ⁴	0.5	1.4	(39.0%)	34.1%	120.0%
Contribution Margin	11.3%	30.6%	(33.7 ppt)	(3.7 ppt)	2.2 ppt
Underlying Contribution Margin ⁴	11.3%	15.5%	(8.7 ppt)	(3.7 ppt)	(1.1 ppt)

Underlying Revenue for 2Q 2021 was £4.8 million (AUS\$8.9 million), up 8.1% on prior quarter (1Q 2021: £4.4 million, AUS\$8.2 million). Increased diagnostic referrals contributed to this revenue increase.

⁴ Underlying Revenue, Underlying Gross Profit, Underlying Gross Profit Margin, Underlying Contribution and Underlying Contribution Margin exclude irregular revenue items such as underwritten volume top-up payments, technology platform licencing fees and digital design service fees. This metric is intended to give a clear view of the underlying operational performance of the business.

One-off payments totalling £2.0 million (AUS\$3.7 million) were recognised in Revenue but excluded from Underlying Revenue in 1Q 2021. No payments of this nature were recognised in 2Q 2021.


Underlying Gross Profit for 2Q 2021 was £1.9 million (AUS\$3.5 million), down 1.6% on prior quarter (1Q 2021: £1.9 million, AUS\$3.5 million), up 47.5% on 2Q20.

Underlying Gross Profit Margin for 2Q 2021 was 39.3%, down 3.9 percentage points on prior quarter (1Q 2021: 43.2%). This was driven by the additional financial incentives paid to doctors given higher than expected demand and pressure on our GPs to allocate increased time to the national vaccine rollout. We expect this reduction to be temporary and for Underlying Gross Profit Margin to normalise over time.

Underlying Contribution for 2Q 2021 was £0.5 million (AUS\$1.0 million), down 39.0% on prior quarter (1Q 2021: £0.9 million, AUS\$1.6 million). This was driven by investment in the team responsible for managing downstream diagnostic referrals, which increased by 34.4% in the quarter, the benefit of which is expected to be realised as diagnostic referrals scale across the remainder of the year.

Underlying Contribution Margin for 2Q 2021 was 11.3%, down 8.7 percentage points on prior quarter (1Q 2021: 20.0%), reflecting the reduction in Gross Profit Margin as well as our increased investment in the management of downstream diagnostic referrals.

Underlying revenue (£m's)



Cash flows

Net operating cash outflows for the quarter were £2.8 million (1Q 2021: £2.4 million outflow), relating to costs of operating DOC's telehealth platform including the cost of employed doctors, patient support functions, software technology costs and corporate overheads, offset by cash receipts from customers.

Net investing cash outflows for the quarter were £0.6 million (1Q 2021: £0.7 million outflow), relating to payments for capital equipment and capitalised development expenses.

Net cash outflows from financing activities for the quarter were £0.2 million (1Q 2021: £0.2 million outflow), mainly relating to costs incurred in the prior year associated with the Company's IPO.

Payments to related parties in the period totalled £0.2 million (1Q 2021: £0.3 million), these represented the payment of Director Fees to Non-Executive Directors and salaries to Executive Directors, including pension and payroll tax payments.

DOC exited the quarter with £31.5 million of cash on hand as at 30 June 2021 (31 March 2021: £35.1 million).

Outlook

DOC reaffirms the FY 2021 guidance provided in its 1Q 2021 results, to deliver at least 100% year-on-year revenue growth in FY 2021.

Further increase in diagnostic referral rates are expected as the UK economy opens up with significant long-term benefits to the Company's revenue streams. DOC continues to assess opportunities to accelerate growth, both domestically and internationally.

Use of Funds

Use of Funds	Prospectus dated 30 October 2020 (£m's) ⁵	2Q 2021 (£m's)	Period to date (£m's) ⁶
Investment in core capabilities to drive greater value from existing services	13.7	1.5	3.8
Investment in new services to drive growth through existing channels	6.4	0.6	1.3
Investment in international business development	1.3	0.1	0.3
Working capital	10.1	1.4	5.3
Costs of the Offer	4.3	-	3.5
Total	35.8	3.6	14.2

Expenditure for 2Q 2021 was in accordance with the Use of Funds outlined in the Company's Prospectus dated 30 October 2020 and there were no material variances against the estimated use of funds.

Investor Webcast

Investors are invited to join a webcast presentation at 9:00am (AEST) on the 2Q 2021 Quarterly Activity Report hosted by CEO Dr Bayju Thakar and CFO Dan Curran.

Investors who wish to attend can register using the following link:

https://us02web.zoom.us/webinar/register/WN_3lrl3QxGQaSvddD8HeOPQQ

Participants are encouraged to submit questions in advance via:

investorenquiries@doctorcareanywhere.com

- ENDS -

This ASX announcement has been authorised for release by the Board of Directors.

About Doctor Care Anywhere:

Doctor Care Anywhere Group PLC is a UK-based telehealth company that is committed to delivering the best possible patient experience and clinical care through digitally enabled, joined up, evidence based pathways on

⁵ AUD: GBP 0.55

⁶ **Period to date** represents the period from 1 October 2020 to 30 June 2021

its proprietary platform. DOC utilises its relationships with health insurers, healthcare providers and corporate customers to connect with patients to deliver a range of telehealth services.

Further Information:
Roger Newby Domestique Consulting – Investor Relations +61 401 278 906
Daniel Curran Chief Financial Officer and Company Secretary company.secretary@doctorcareanywhere.com

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Doctor Care Anywhere Group PLC

ARBN

645 163 873

Quarter ended ("current quarter")

30 June 2021

Consolidated statement of cash flows		Current quarter £'000	Year to date (6 months) £'000
1.	Cash flows from operating activities		
1.1	Receipts from customers	6,529	12,285
1.2	Payments for		
	(a) research and development	(1,078)	(1,678)
	(b) product manufacturing and operating costs	(3,977)	(7,011)
	(c) advertising and marketing	(300)	(603)
	(d) leased assets	-	-
	(e) staff costs	(2,276)	(4,932)
	(f) administration and corporate costs	(1,581)	(3,114)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	1	1
1.5	Interest and other costs of finance paid	(1)	(1)
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	-	-
1.8	Other (provide details if material)	(125)	(140)
1.9	Net cash from / (used in) operating activities	(2,807)	(51,193)
2.	Cash flows from investing activities		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	(192)	(365)

Consolidated statement of cash flows		Current quarter £'000	Year to date (6 months) £'000
	(d) investments	-	-
	(e) intellectual property	(402)	(905)
	(f) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(g) entities	-	-
	(h) businesses	-	-
	(i) property, plant and equipment	-	-
	(j) investments	-	-
	(k) intellectual property	-	-
	(l) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	(594)	(1,270)

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	15	15
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	(111)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	(223)	(276)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	Net cash from / (used in) financing activities	(208)	(372)

Consolidated statement of cash flows		Current quarter £'000	Year to date (6 months) £'000
4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	35,101	38,360
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(2,807)	(5,193)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(594)	(1,270)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(208)	(372)
4.5	Effect of movement in exchange rates on cash held	(18)	(51)
4.6	Cash and cash equivalents at end of period	31,473	31,473

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter £'000	Previous quarter £'000
5.1	Bank balances	31,473	35,101
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	31,473	35,101

6.	Payments to related parties of the entity and their associates	Current quarter £'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	158
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

7.	Financing facilities <i>Note: the term "facility" includes all forms of financing arrangements available to the entity.</i> <i>Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	Total facility amount at quarter end £'000	Amount drawn at quarter end £'000
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	-	-
7.4	Total financing facilities	-	-
7.5	Unused financing facilities available at quarter end		-
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		
	n/a		

8.	Estimated cash available for future operating activities	£'000
8.1	Net cash from / (used in) operating activities (item 1.9)	(2,807)
8.2	Cash and cash equivalents at quarter end (item 4.6)	31,473
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	31,473
8.5	Estimated quarters of funding available (item 8.4 divided by item 8.1)	11
	<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6	If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1	Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
	Answer: n/a	
8.6.2	Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
	Answer: n/a	
8.6.3	Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
	Answer: n/a	
	<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>	

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 27 July 2021

Authorised by: Board of Directors
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – e.g. Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.